Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31.
The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast.
Novo has spent 2026 trying to prove it can grow beyond Wegovy and Ozempic, and this was one of the clearest tests of that plan.
For anyone holding the stock or watching the dip, the reaction says a lot about how much the market had riding on this trial.
Novo Nordisk stock falls after its ZEUS heart drug trial misses
Novo Nordisk started July 31 with one of its worst trading sessions in months.
The company said its heart drug Ziltivekimab failed the main goal of the ZEUS trial, and investors sold the stock fast.
Novo Nordisk’s Danish shares fell about 7.5% on the day, while the company’s U.S.-listed shares dropped 8.6% in early trading, CNBC reported.
The drop shows how much investors were counting on Ziltivekimab to become a second growth engine next to Novo’s weight-loss and diabetes drugs.
That hope is now on hold, and the stock reaction reflects it.
What the ZEUS trial tested and why it failed
ZEUS was a late-stage trial that followed more than 6,300 people, according to Novo Nordisk’s press release.
The patients had atherosclerotic cardiovascular disease, chronic kidney disease, and ongoing inflammation. That last group matters because inflammation is linked to heart attacks and strokes.
Ziltivekimab is a once-monthly injection that blocks a protein called IL-6, which drives inflammation in the body.
More Healthcare Stocks:
- Goldman Sachs sees writing on the wall for Eli Lilly stock
- UBS strongly resets Lilly stock target
- JPMorgan resets LLY stock target on drug demand
Novo wanted to show that lowering inflammation would also lower the rate of major adverse cardiovascular events, like heart attack, stroke, or cardiovascular death.
The drug did lower inflammation markers as designed, but that biological effect did not turn into fewer heart events.
The trial posted a hazard ratio of 0.99, which means patients on the drug had almost the same risk as patients on a placebo.
One safety detail stood out. Patients on Ziltivekimab had more serious infections than those on placebo, though overall death rates were similar between the two groups.
Why the failure hit Novo Nordisk stock so hard
Novo has spent 2026 trying to prove it can grow beyond Wegovy and Ozempic.
Analysts widely expected Ziltivekimab to deliver at least some heart benefit and eventually reach billions in annual sales.
Without that win, Novo’s cardiovascular pipeline outside of weight-loss drugs now looks weaker, and investors sold the stock to reflect that.
Related: Ozempic maker takes biggest rival to court over weight-loss drug ads
Novo Nordisk said the setback will cost it money on paper. The company expects to take a non-cash impairment charge in the third quarter of 2026 tied to this trial failure.
An impairment charge is an accounting write-down that lowers the recorded value of an asset. It does not drain cash, but it signals that a project is worth less than expected.
Novo also confirmed the failure will not change its 2026 adjusted operating profit outlook, so the near-term earnings outlook stays intact.
How this fits Novo Nordisk’s rough stretch in 2026
Novo shares have fallen sharply from their 2024 highs as Eli Lilly (LLY) has taken GLP-1 market share with Mounjaro and Zepbound.
The failure also arrives days after a U.S. judge ruled Novo must face part of a shareholder lawsuit tied to its CagriSema weight-loss trial, CNBC reported.
That case centers on what Novo told investors about the design of the REDEFINE-1 trial before disappointing results in December 2024, Pharmaphorum reported.
The concern for some investors is repetition. Novo keeps building expectations for pipeline drugs, then falling short of the biggest targets.
What could still go right for Novo’s heart drug
The heart program still has two chances left to prove itself.
Novo Chief Scientific Officer Martin Holst Lange said the ZEUS result does not change the company’s commitment to cardiovascular disease, CNBC noted.
Ziltivekimab is still being tested in two other late-stage trials with different patient groups:
- HERMES, which studies patients with heart failure
- ARTEMIS, which studies patients recovering from an acute heart attack
Both trials continue, and Novo expects results in the first half of 2027.
A positive result in either trial would reopen the cardiovascular opportunity that ZEUS just closed, though there is no guarantee the drug performs better in those patients.
What Novo Nordisk investors should watch next
The clearest early signal comes at Novo’s next earnings report, when its management is expected to disclose the size of the impairment charge and update its pipeline plans.
Here are three things worth tracking:
- The impairment charge. The dollar figure in the Q3 2026 report will show how much value Novo assigned to the ZEUS program.
- Wegovy pill momentum. U.S. prescription trends for the oral version will indicate whether the core business can keep funding new bets.
- The CagriSema lawsuit. Any movement in the shareholder case could affect sentiment separate from the drug pipeline.
Novo also plans to present the full ZEUS data at a medical meeting later in 2026, which may reveal whether any patient subgroup saw a benefit.
Until then, the core diabetes and obesity business remains the main reason to own the stock, and the heart pipeline remains an open question.
The failure does not threaten Novo’s current revenue, but it removes one path the company was counting on to widen its lead over Lilly.
The bigger question for investors is whether Novo’s stock price already accounts for this setback. Shares have traded lower for months as Eli Lilly gains ground in the weight-loss drug market, so some of this bad news may already be priced in.
Anyone taking a position should size it to their own risk tolerance, since a single trial result or court ruling can still move this stock sharply.
Related: Lilly quietly hands Chinese partner its cancer drug
